Professor of Medicine, Brigham and Women's Hospital
Cardiology
Dr. Elizabeth G. Nabel, MD
|
|
Give Review
Dr. Elizabeth G. Nabel is an expert in the field of Cardiology. She researched medicine at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine She over the years received 10 awards: "Distinguished Bostonian Award", "50 Most Powerful People", "Kober Medal", "Champion in Health Care Award", "Elected Member", "Eugene Braunwald Academic Mentorship Award", "Willem Einthoven Award", "Fellow", "Distinguished Achievement Award" and "Whos Who in Medicine and Healthcare". Elizabeth G. Nabel has written publications. She has 99 publications published with PubMed. The lastest paper is: 'Requirements for enhanced transgene expression by untranslated sequences from the human cytomegalovirus immediate-early gene.'
Publications
- The Women's Health Initiative-A Victory for Women and Their Health.
- Cardiovascular insights from a premature aging syndrome: a translational story.
- A tale of coronary artery disease and myocardial infarction.
- Genomics of cardiovascular disease.
- Prmt2 Regulates the Lipopolysaccharide-Induced Responses in Lungs and Macrophages.
- A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention.
- Progerin and telomere dysfunction collaborate to trigger cellular senescence in normal human fibroblasts.
- Cellular senescence, vascular disease, and aging: part 2 of a 2-part review: clinical vascular disease in the elderly.
- Cellular senescence, vascular disease, and aging: part 1 of a 2-part review.
- Protein farnesylation inhibitors cause donut-shaped cell nuclei attributable to a centrosome separation defect.
- Differential Temporal and Spatial Progerin Expression during Closure of the Ductus Arteriosus in Neonates.
- Correction: Differential Temporal and Spatial Progerin Expression during Closure of the Ductus Arteriosus in Neonates.
- Cardiovascular pathology in Hutchinson-Gilford progeria: correlation with the vascular pathology of aging.
- Disruption of protein arginine N-methyltransferase 2 regulates leptin signaling and produces leanness in vivo through loss of STAT3 methylation.
- Deficiency of cyclin-dependent kinase inhibitors p21Cip1 and p27Kip1 accelerates atherogenesis in apolipoprotein E-deficient mice.
- On board with the Cures Acceleration Network.
- Why data-sharing policies matter.
- Linking biomedical research to health care.
- National Heart, Lung, and Blood Institute perspective: lung progenitor and stem cells--gaps in knowledge and future opportunities.
- The global alliance for chronic diseases.
- Neuropilin-1 identifies endothelial precursors in human and murine embryonic stem cells before CD34 expression.
- Notes from the Director, National Heart, Lung, and Blood Institute: transitions.
- The cardiovascular programs of the National Heart, Lung, and Blood Institute: from vision to action to impact.
- National Heart, Lung, and Blood Institute: transitions.
- CABG vs. stenting--clinical implications of the SYNTAX trial.
- Notes from the NHLBI director: transitions.
- KIS protects against adverse vascular remodeling by opposing stathmin-mediated VSMC migration in mice.
- A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model.
- Protecting aggregate genomic data.
- Cardiovascular genomics, personalized medicine, and the National Heart, Lung, and Blood Institute: part I: the beginning of an era.
- A recommitment to sickle cell disease research.
- The physician-scientist: a value proposition.
- Pharmacogenomics--ready for prime time?
- Phenotype and course of Hutchinson-Gilford progeria syndrome.
- GA-binding protein regulates KIS gene expression, cell migration, and cell cycle progression.
- Shaping the future of research: the NHLBI strategic plan.
- Notes from the NHLBI director: shaping the future of research--the NHLBI strategic plan.
- Notes from the director of the National Heart, Lung, and Blood Institute: shaping the future of research: the NHLBI strategic plan.
- Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide.
- Notes from the NHLBI Director: National Heart, Lung, and Blood Institute core values and shaping the 2007 budget.
- Notes from the Director, National Heart, Lung, and Blood Institute: NHLBI core values and shaping the 2007 budget.
- Mechanisms of cardiovascular disease in accelerated aging syndromes.
- Treating COPD.
- Detection of venous thromboembolism by proteomic serum biomarkers.
- Conflict of interest--or conflict of priorities?
- Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts.
- The Women's Health Initiative.
- The arginine methyltransferase PRMT2 binds RB and regulates E2F function.
- Response to: "Rescuing the NIH before it is too late".
- Protein methyltransferase 2 inhibits NF-kappaB function and promotes apoptosis.
- Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome.
- NIH research on obesity and type 2 diabetes: providing the scientific evidence base for actions to improve health.
- Genomics of in-stent restenosis: early insights into a complex disease.
- Notes from the Director National Heart, Lung, and Blood Institute: fostering the independence of new investigators.
- Notes from the NHLBI director: fostering the independence of new investigators.
- Fostering the independence of new investigators.
- Notes from the NHLBI Director: a vision for the future: opportunities and challenges.
- A vision for the future: notes from the NHLBI director.
- A vision for the future: opportunities and challenges: notes from the director of the National Heart, Lung, and Blood Institute.
- A vision for the future: opportunities and challenges.
- Interview with Dr. Elizabeth G. Nabel, Director, National Heart, Lung, and Blood Institute. Interview by Stuart F. Quan.
- Bone marrow-derived immune cells regulate vascular disease through a p27(Kip1)-dependent mechanism.
- Retinoic acid causes cell growth arrest and an increase in p27 in F9 wild type but not in F9 retinoic acid receptor beta2 knockout cells.
- Cardiovascular disease.
- p21(CIP1) Controls proliferating cell nuclear antigen level in adult cardiomyocytes.
- The cell cycle and cardiovascular diseases.
- What can cardiovascular gene transfer learn from genomics: and vice versa?
- Angiotensin-converting enzyme 2--a new cardiac regulator.
- Stem cells combined with gene transfer for therapeutic vasculogenesis: magic bullets?
- Gene transfer to arteries.
- The golden egg--making good on discovery and translation.
- Reflections on a life in biomedicine: leading change.
- Adenovirus-mediated gene transfer of VEGF(121) improves lower-extremity endothelial function and flow reserve.
- Detection of atherosclerosis using a novel positron-sensitive probe and 18-fluorodeoxyglucose (FDG).
- Cell cycle and cell migration: new pieces to the puzzle.
- Heme oxygenase-1 protects against vascular constriction and proliferation.
- Coexpression of guanylate kinase with thymidine kinase enhances prodrug cell killing in vitro and suppresses vascular smooth muscle cell proliferation in vivo.
- Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity.
- SM22alpha promoter targets gene expression to vascular smooth muscle cells in vitro and in vivo.
- Coronary heart disease in women--an ounce of prevention.
- Restricted expression of an adenoviral vector encoding Fas ligand (CD95L) enhances safety for cancer gene therapy.
- Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury.
- Differential effects of the cyclin-dependent kinase inhibitors p27(Kip1), p21(Cip1), and p16(Ink4) on vascular smooth muscle cell proliferation.
- Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation.
- Atherosclerosis progression in LDL receptor-deficient and apolipoprotein E-deficient mice is independent of genetic alterations in plasminogen activator inhibitor-1.
- New approaches to pulmonary hypertension: will therapies in mice work in humans?
- Prospects for genetic therapy of cardiovascular disease.
- Plasminogen activator inhibitor-1 and vitronectin promote vascular thrombosis in mice.
- Gene therapy for coronary artery disease: The University of Michigan Program.
- Gene therapy for cardiovascular diseases.
- Requirements for enhanced transgene expression by untranslated sequences from the human cytomegalovirus immediate-early gene.
- Delivering genes to the heart--right where it counts!
- Combination gene delivery of the cell cycle inhibitor p27 with thymidine kinase enhances prodrug cytotoxicity.
- Graft permeabilization facilitates gene therapy of transplant arteriosclerosis in a rabbit model.
- Gene transfer into normal and atherosclerotic human blood vessels.
- Gene transfer approaches to the regulation of vascular cell proliferation.
- Genetic therapy.
- Expression of cyclin-dependent kinase inhibitors in vascular disease.
Schools
Weill Cornell Medical College
Doctors Specialties
- Cardiology
Accepted Insurances
Awards
- Distinguished Bostonian Award
- 50 Most Powerful People
- Kober Medal
- Champion in Health Care Award
- Elected Member
- Eugene Braunwald Academic Mentorship Award
- Willem Einthoven Award
- Fellow
- Distinguished Achievement Award
- Whos Who in Medicine and Healthcare
Education
-
Brigham and Women's Hospital -
Weill Cornell Medical College of Cornell University
Hospital
-
Brigham and Women's Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Rajesh Gupta, MD |
|
|
Dr. Abdul Basit, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew Sherwood, MD |
|
|
Dr. Aidan W. Flynn, MD |
|
|
Dr. Jose M. Silva, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Thomas Metkus, MD |
|
|
Dr. Pipin Kojodjojo, PHD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John A. Jarcho, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathryn A. Britton, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peter M. Kang, MD |
|
|
Dr. Steven A. Lubitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. Gerszten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Aloke V. Finn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen D. Wiviott, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malissa J. Wood, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Moussa C. Mansour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert O. Blaustein, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Hong Jun Yun, MD |